Pharmaceutical maker Novartis AG says a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.
By fox5vegas.com
Pharmaceutical maker Novartis AG says a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.
By fox5vegas.com